Becton, Dickinson and Co. announced the completion of its acquisition of Carmel Pharma, a Swedish company that manufactures the PhaSeal System.

The company said that it expects fully diluted earnings per share to be adversely impacted by the acquisition in fiscal year 2011 by approximately $0.05, which was not included in the fiscal year 2011 earnings guidance the Company provided in connection with the release of its third fiscal quarter earnings.